Cyclacel Pharmaceuticals, Inc. (CYCC) earnings
CYCC earnings moved a median of -1.00% by the close. Quarterly and annual CYCC reports and results, each read against the price at its own news timestamp. Back to the CYCC overview →
17 measured CYCC earnings events.
Where these CYCC earnings landedvs 17 measured CYCC earnings reactions
| Middle 50% of CYCC earnings reactions | -4.17% to +1.95% |
|---|---|
| Median reaction (to close) | -1.00% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 CYCC earnings events with a measured close landed between -4.17% and +1.95%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Cyclacel Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +1.77% | +1.95% | |
| Form 10-Q Cyclacel Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +1.00% | -5.58% | |
| Form 10-K Cyclacel Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.00% | -4.17% | |
| Form NT 10-K Cyclacel Pharmaceuticals For: Dec 31 | SEC filing · Form NT | -1.05% | +0.87% | |
| Form 10-Q Cyclacel Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +6.21% | +8.22% | |
| Form 10-Q Cyclacel Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +0.70% | -7.69% | |
| Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results | Press release | +0.00% | -2.30% | |
| Form 10-Q Cyclacel Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -3.92% | -13.17% | |
| Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results | Press release | -0.30% | +8.92% | |
| Form 10-K/A Cyclacel Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -6.74% | +9.85% | |
| Form 10-K Cyclacel Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.00% | +4.69% | |
| Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC | Press release | -3.78% | -10.07% | |
| Form 10-K/A Cyclacel Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.00% | -1.00% | |
| Form 10-Q Cyclacel Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.00% | |
| Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q | Press release | +0.00% | -1.00% | |
| Form NT 10-Q Cyclacel Pharmaceuticals For: Sep 30 | SEC filing · Form NT | +2.29% | +0.29% | |
| Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results | Press release | +0.00% | -2.27% |
Keep exploring
More CYCC: analyst actions → · SEC filings → · CYCC overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MeiraGTx Holdings plc - Ordinary Shares (MGTX) | 239 | -0.10% | 46% |
| Ovid Therapeutics Inc. (OVID) | 239 | -0.32% | 40% |
| RESTORBIO (TORC) | 238 | -0.17% | 46% |
| Retractable Technologies, Inc. (RVP) | 237 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.